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Non-alcoholic fatty liver disease (NAFLD), with a 
prevalence of approximately 20-30% in adult population, 
is increasingly recognized as the most common cause of 
chronic liver disease in Western Countries, and it is typically 
associated with obesity, type II diabetes and hyperlipidemia 
as the most important risk factors (1). The term NAFLD 
refers to a complex spectrum of conditions ranging from 
benign fatty liver, to non-alcoholic steatohepatitis (NASH), 
characterized by necro-inflammation and fibrosis and 
may further progress into cirrhosis and its complications, 
including hepatocellular carcinoma (HCC) (1).
The earliest manifestation and hallmark of NAFLD 
is hepatic steatosis, which is defined as intracellular 
accumulation of triglycerides in hepatocytes. Since an 
early diagnosis of NAFLD is recommended (2), patients 
with liver enzymes abnormalities in serum or sonographic 
findings of increased hepatic echogenicity, particularly 
in presence of metabolic risk factors, are directed to 
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liver biopsy (LB). Histopathology is considered the 
reference standard for NAFLD diagnosis, grading and 
characterization, being capable to identify intracellular 
triglyceride accumulation, classify the degree of steatosis 
into semi-quantitative categories and distinguish among the 
different conditions which constitute NAFLD spectrum (3). 
However, LB has several drawbacks, mostly including its 
observer-dependence and, of course, its invasiveness, which 
limits its usefulness especially in the follow-up of NAFLD 
patients.
For these reasons, imaging surrogates for the assessment 
of hepatic steatosis have been investigated, not only for 
early detection of disease, but also to reliably quantify 
the severity of disease, using histology as the reference 
standard. Among non-invasive imaging techniques, MR is 
the most accurate for NAFLD diagnosis and grading, both 
with respect to MR spectroscopy (MRS) and MR imaging 
(MRI) (4).
1H MRS allows the in-vivo study of liver molecular 
composition, usually showing the two dominant peaks of 
water and methylene protons of fatty acids, thus allowing 
to calculate the proportion of hepatic proton density which 
is attributable to fat. This MR quantitative biomarker of 
liver fat content (LFC) is called proton density fat fraction 
(PDFF) (5). Unfortunately, 1H MRS is time-consuming 
and not available on all clinical scanners, remaining mainly 
a research tool radiologists are not used to work with. 
Furthermore, single voxel-MRS has the same limitation of 
LB when considering the limited sample size.
Several MRI techniques have been used for the 
assessment of hepatic steatosis, all with the objective to 
obtain water and fat separation. Fat suppression techniques, 
based on the use of selective saturation or excitation 
pulses, or on short-tau inversion recovery (STIR) imaging, 
have been used since the 1980s. T2-weighted fast spin-
echo MRI with and without fat suppression have shown 
controversial results in the quantification of LFC calculated 
as the percentage of relative signal intensity loss of the liver 
on fat-saturated images, usually using spleen as the tissue 
of reference (6,7). These techniques are limited by their 
sensitivity to B0 and B1 inhomogeneities or by reduced 
signal to noise ratio. Besides, they are affected by low scan 
time efficiency (8).
In-opposed-phase MRI techniques rely on the water/fat 
chemical shift difference to achieve water and fat separation 
by using different TEs (echo times). Since the first of 
these methods was introduced by Dixon in 1984 (9), many 
researchers have made modifications to the Dixon method 
to decrease its sensitivity to magnetic field inhomogeneity, 
e.g., with the “three-point” method proposed by Glover 
et al. (10), and to reduce scan time, particularly with 
the introduction of fast Gradient Echo techniques (11). 
Opposed-phase liver signal intensity loss, obtained by using 
T1-weighted dual-phase gradient-echo sequence, has been 
largely investigated as a biomarker of hepatic steatosis, 
showing quite accurate results (6,7,12).
However, with these MRI techniques, LFC is still 
calculated as a “fat signal fraction” from water and fat 
signal intensities rather than proton densities. Some 
technical measures have been introduced to increase MRI 
performance and minimize the effect of confounding 
factors which affect fat quantification when using in-
opposed phase techniques. First, the optimal signal to noise 
ratio has been achieved by applying a combined gradient-
echo multipoint water-fat separation known as “iterative 
decomposition of water and fat with echo asymmetry and 
least squares estimation” (IDEAL) (13). Subsequently, the 
use of a low flip angle has been introduced to address the 
effect of T1 (14), and furthermore a multiecho gradient-
recalled-echo MRI has been proposed, with the multiecho 
acquisition allowing the estimation and the correction 
of T2* effect (15,16). The recent introduction of this 
technique is particularly remarkable because it allows 
to overcome the potential pitfall, typical of dual-phase 
imaging, due to the well known effect of iron overload on 
T2* decay (17). Indeed, T2* estimation can also be used as 
a simultaneous biomarker of hepatic iron overload, which 
has been reported to occur in patients with NAFLD (18). 
Finally, to improve separation of water and fat by addressing 
multifrequency interference effects of fat protons, some 
authors have incorporated spectral modeling of fat with 
multipeak reconstruction, assuming that the multiple, 
typically six, resonance frequencies and relative amplitudes 
of fat are known a priori, based on spectroscopy-derived 
measurements (18,19).
By using all of these technical precautions to address 
confounding factors, “fat signal fraction” turns to be 
equivalent to PDFF, and MRI can finally be used to estimate 
LFC based on proton densities. In fact, some studies 
demonstrated a high agreement between T1-independent 
T2*-corrected MRI with spectral modeling of fat and 
MRS (18). Therefore, it has to be further stressed that, 
based on the kind of technique being used, MR biomarkers 
of LFC reflect different physical entities, basically obtaining 
fat fractions which can be calculated from signal intensity or 
proton densities. 
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Tang et al. (20) evaluated the diagnostic performance 
of MRI-estimated PDFF, obtained by applying a low flip 
angle, multiple TEs and multipeak fat spectral modeling, 
in the assessment of hepatic steatosis in a relatively large 
population of patients with NAFLD. A remarkable 
aspect of their work is that, while most prior study on 
this topic relied on fat-water phantoms or MRS, Tang 
et al. used histopathology as the reference standard, since 
it is the current clinical and research gold standard for 
steatosis. Furthermore, performing pathological analyses 
allowed them to evaluate the relationship between several 
concomitant histological confounding factors and imaging 
PDFF.
One of the main elements of novelty of this study is 
the identification of MRI thresholds based on PDFF to 
classify patients into different steatosis categories, with 
histopathological grades as the reference standard. A few 
other studies indicated threshold values, but they were 
obtained using simpler MRI techniques (12,21). Noticeably, 
the obtained cut-off PDFF value to differentiate normal 
from abnormal fat fraction was similar, even though slightly 
higher, to that reported by a previous study which used 
MRS (22). It is well known that histological and MRI 
estimated steatosis percentages are not directly comparable 
because they refer to different entities, namely fat-
containing hepatocytes and mobile fat protons. Therefore, 
since clinicians are used to histopathological grades, the 
attempt to find MRI fat fraction thresholds addresses the 
need to give clinical relevance to the estimated PDFF 
resulting from MRI examinations.
However, as acknowledged by the authors, the obtained 
thresholds are to be further explored and validated in larger 
and more diverse cohorts. In this context, it should be noted 
that the large majority of the studied patients were children. 
Moreover, PDFF thresholds could have been influenced 
by the use of different scanners throughout the study, since 
a slight discrepancy in PDFF estimates with the 1.5 and 
3 T scanners has been previously reported (23). Finally, 
in NAFLD/NASH patients, a large variability of liver 
metabolites and consequently of the fat spectrum is to be 
expected. For this reason, it would be interesting to further 
analyze PDFF thresholds by introducing a spectrum self-
calibration algorithm, as proposed by Yu et al. (19), rather 
than relying on a fat spectrum known a priori, to reduce the 
sensitivity to spectrum variation.
Regardless the identification of PDFF thresholds could 
be clinically important to obtain MRI steatosis categories, 
it should also be said that one of the major advantages 
of MR lies in providing a quantitative biomarker for 
steatosis assessment, i.e., PDFF, rather than giving a 
semi-quantitative grading as does histopathology. MR 
can objectively and reliably measure LFC changes 
which are much slighter than those assessable with 
histology, and with no real need for categories. In other 
words, if the purpose of MR steatosis measurement is to 
diagnose NAFLD, the use of categories can be useful and 
appropriate. If MR is employed during patient follow-up, 
with the aim to identify slight changes in LFC, the use of 
such wide categories can be less convenient respect to the 
exact steatosis percentage.
Because of the invasiveness, the observer-dependence 
and the semi-quantitative grading, the role of LB as a 
gold standard for steatosis assessment has been questioned 
before (24). Besides, many researchers used MRS as the 
reference standard for the validation of MRI techniques, 
or even in longitudinal clinical studies (4) and to determine 
the prevalence of NAFLD (22). With the new refined 
techniques which can reliably quantify PDFF, also MRI 
is an appropriate candidate for the replacement of LB in 
the quantification of hepatic steatosis. Furthermore, when 
compared to MRS, MRI is much more accessible, less 
time-consuming, and it allows to non-invasively evaluate 
the whole liver parenchyma, resulting in a more complete 
assessment of LFC (25). This is particularly relevant 
because of the inherent heterogeneity of NAFLD, which 
limits mostly LB (less than 1/50,000th of the liver available 
for histological analysis), but also single-voxel MRS, which 
usually includes about 8-27 g of liver parenchyma in a 
voxel.
In conclusion, MR, providing a robust quantitative 
biomarker of hepatic steatosis, is a promising non-invasive 
alternative to LB as the gold standard for steatosis diagnosis 
and quantification, especially useful in NAFLD patients 
who require follow-up examinations or in longitudinal 
studies. Unfortunately, MRI, as well as MRS, is still 
limited in the characterization of NAFLD, being unable 
to distinguish between fatty liver and NASH up to now. 
Research is going on in this field, with several promising 
techniques addressing the need to identify and grade necro-
inflammatory activity and fibrosis. Indeed, to finally allow 
the replacement of LB in the comprehensive assessment of 
NAFLD, imaging biomarkers of NASH are still needed.
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